文献速递妇科生殖医学

多囊卵巢综合征女性肠道细菌组与情绪障碍的关系

Gut bacteriome and mood disorders in women with PCOS.
PubMed 文献 · Hum Reprod · 2024-01-01

基于芬兰北部出生队列1966的队列研究,纳入102例PCOS女性和205名年龄及BMI匹配的无PCOS女性,按情绪障碍(MD)标准分组。伴MD的PCOS女性肠道细菌组α多样性较低且丁酸球菌属丰度显著低于不伴MD的PCOS女性。对照组中肠道细菌组不因MD而不同,提示PCOS可能进一步调节肠道细菌组与MD的关联。

要点

  • 伴情绪障碍的PCOS女性肠道细菌组α多样性较低。
  • 伴情绪障碍的PCOS女性丁酸球菌属丰度显著降低。
  • 对照组中肠道细菌组不因情绪障碍而不同。

核心结论

  • 肠道细菌组与情绪障碍相关,且不受PCOS状态影响,但PCOS可能进一步调节肠道细菌组与情绪障碍的关联。

研究设计与样本

  • 基于芬兰北部出生队列1966的人群队列研究,纳入46岁时提供粪便样本的102例PCOS女性和205名年龄及BMI匹配的无PCOS女性。
  • 按已验证的情绪障碍标准分为PCOS无MD组(n=84)、PCOS伴MD组(n=18)、对照无MD组(n=180)和对照伴MD组(n=25)。
  • 临床特征在31岁和46岁时评估,46岁时采集粪便样本,采用16S rRNA测序分析肠道细菌组。

主要发现

  • PCOS伴MD组较PCOS无MD组α多样性降低:Observed feature中位数272 vs 208(FDR=0.01),Shannon指数中位数5.95 vs 5.57(FDR=0.01)。
  • PCOS伴MD组较PCOS无MD组丁酸球菌属丰度降低(ANCOM-BC log-fold change=-0.90,FDRANCOM-BC=0.04)。
  • 对照组中肠道细菌组不因情绪障碍而不同。
  • PCOS组中Sutterella与肥胖相关临床参数正相关:BMI(r²=0.31,FDR=0.01)、腰围(r²=0.29,FDR=0.02)。
  • PCOS组中Sutterella与糖代谢及肠道屏障完整性指标正相关:空腹血糖(r²=0.46,FDR<0.001)、空腹胰岛素(r²=0.24,FDR=0.05)、连蛋白(r²=0.25,FDR=0.03)。

局限性

  • 虽然这是首个评估PCOS中肠道细菌组与情绪障碍关联的研究,并纳入最大的PCOS肠道微生物组数据集,但按情绪障碍分层后的受试者数量有限,与既往关注非选择人群情绪障碍的研究相比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How does the gut bacteriome differ based on mood disorders (MDs) in women with polycystic ovary syndrome (PCOS), and how can the gut bacteriome contribute to the associations between these two conditions? SUMMARY ANSWER: Women with PCOS who also have MDs exhibited a distinct gut bacteriome with reduced alpha diversity and a significantly lower abundance of Butyricicoccus compared to women with PCOS but without MDs. WHAT IS KNOWN ALREADY: Women with PCOS have a 4- to 5-fold higher risk of having MDs compared to women without PCOS. The gut bacteriome has been suggested to influence the pathophysiology of both PCOS and MDs. STUDY DESIGN, SIZE, DURATION: This population-based cohort study was derived from the Northern Finland Birth Cohort 1966 (NFBC1966), which includes all women born in Northern Finland in 1966. Women with PCOS who donated a stool sample at age 46 years (n = 102) and two BMI-matched controls for each case (n = 205), who also responded properly to the MD criteria scales, were included. PARTICIPANTS/MATERIALS, SETTING, METHODS: A total of 102 women with PCOS and 205 age- and BMI-matched women without PCOS were included. Based on the validated MD criteria, the subjects were categorized into MD or no-MD groups, resulting in the following subgroups: PCOS no-MD (n = 84), PCOS MD (n = 18), control no-MD (n = 180), and control MD (n = 25). Clinical characteristics were assessed at age 31 years and age 46 years, and stool samples were collected from the women at age 46 years, followed by the gut bacteriome analysis using 16 s rRNA sequencing. Alpha diversity was assessed using observed features and Shannon's index, with a focus on genera, and beta diversity was characterized using principal components analysis (PCA) with Bray-Curtis Dissimilarity at the genus level. Associations between the gut bacteriome and PCOS-related clinical features were explored by Spearman's correlation coefficient. A P-value for multiple testing was adjusted with the Benjamini-Hochberg false discovery rate (FDR) method. MAIN RESULTS AND THE ROLE OF CHANCE: We observed changes in the gut bacteriome associated with MDs, irrespective of whether the women also had PCOS. Similarly, PCOS MD cases showed a lower alpha diversity (Observed feature, PCOS no-MD, median 272; PCOS MD, median 208, FDR = 0.01; Shannon, PCOS no-MD, median 5.95; PCOS MD, median 5.57, FDR = 0.01) but also a lower abundance of Butyricicoccus (log-fold changeAnalysis of Compositions of Microbiomes with Bias Correction (ANCOM-BC)=-0.90, FDRANCOM-BC=0.04) compared to PCOS no-MD cases. In contrast, in the controls, the gut bacteriome did not differ based on MDs. Furthermore, in the PCOS group, Sutterella showed positive correlations with PCOS-related clinical parameters linked to obesity (BMI, r2=0.31, FDR = 0.01; waist circumference, r2=0.29, FDR = 0.02), glucose metabolism (fasting glucose, r2=0.46, FDR < 0.001; fasting insulin, r2=0.24, FDR = 0.05), and gut barrier integrity (zonulin, r2=0.25, FDR = 0.03). LIMITATIONS, REASONS FOR CAUTION: Although this was the first study to assess the link between the gut bacteriome and MDs in PCOS and included the largest PCOS dataset for the gut microbiome analysis, the number of subjects stratified by the presence of MDs was limited when contrasted with previous studies that focused on MDs in a non-selected population. WIDER IMPLICATIONS OF THE FINDINGS: The main finding is that gut bacteriome is associated with MDs irrespective of the PCOS status, but PCOS may also modulate further the connection between the gut bacteriome and MDs. STUDY FUNDING/COMPETING INTEREST(S): This research was funded by the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie Grant Agreement (MATER, No. 813707), the Academy of Finland (project grants 315921, 321763, 336449), the Sigrid Jusélius Foundation, Novo Nordisk Foundation (NNF21OC0070372), grant numbers PID2021-12728OB-100 (Endo-Map) and CNS2022-135999 (ROSY) funded by MCIN/AEI/10.13039/501100011033 and ERFD A Way of Making Europe. The study was also supported by EU QLG1-CT-2000-01643 (EUROBLCS) (E51560), NorFA (731, 20056, 30167), USA/NIH 2000 G DF682 (50945), the Estonian Research Council (PRG1076, PRG1414), EMBO Installation (3573), and Horizon 2020 Innovation Grant (ERIN, No. EU952516). The funders did not participate in any process of the study. We have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Lee S, Tejesvi MV, Hurskainen E, et al. Gut bacteriome and mood disorders in women with PCOS. Hum Reprod. 2024. PMID: 38614956. doi:10.1093/humrep/deae073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。